Foundation for Prader-Willi Research

Foundation for Prader-Willi Research

The Foundation for Prader-Willi Research (FPWR) was launched in 2003 by a group of parents, including Executive Director Susan Hedstrom, whose child was diagnosed with the complex genetic disorder. The organization emerged not as a passive grantmaker but as an activist research accelerator, frustrated by the slow pace of academic inquiry into the condition. FPWR channels family-raised funds directly into translational science, operating with the urgency of a biotech startup rather than a traditional medical charity. FPWR deploys capital across a narrow but deep pipeline: basic science exploring the genetic mechanisms of Prader-Willi syndrome (PWS), clinical trials for hyperphagia treatments, and translational studies in animal models. The foundation does not operate as a multi-asset allocator; its deployment is concentrated in direct, milestone-based research grants. Known funded research includes studies on oxytocin-based therapies and genetic reactivation approaches through collaborators at academic centers. FPWR’s grant model often requires investigators to hit specific data-sharing and translational benchmarks, a structure borrowed from venture capital. Its geographic footprint spans the United States and Canada, with patient-registry data flowing internationally. FPWR manages a multimillion-dollar annual research budget, powered by grassroots fundraising events like the One Small Step walk series and major donor contributions. The organization lacks a formal professional team count in public records but maintains a network of scientific advisors and a remote-first staff supporting its global registry, study coordination, and advocacy. FPWR anchors a broader consortium called the Global PWS Registry, aggregating patient-reported outcomes to de-risk trial enrollment for biopharma partners. A dated operational milestone: in 2023, FPWR publicly marked two decades of work, noting that its funded science had moved three separate drug candidates into human clinical testing (per the firm's official communications). FPWR’s structural distinction lies in its venture-philanthropy posture. It does not merely fund science; it builds the enabling infrastructure — patient registries, natural history studies — that large biopharma firms rely on to justify PWS drug trials. This places a modest foundation at the nexus of a commercial drug-development funnel for an underserved patient population, giving it influence disproportionate to its size.